Latest Mylan Inc (MYL) Headlines Mylan Comments
Post# of 105
Posted On: 03/13/2014 11:27:03 AM
Latest Mylan Inc (MYL) Headlines
Mylan Comments on Favorable Ruling in Generic Celebrex® Patent Suit
PR Newswire - Thu Mar 13, 5:30AM CDT
Mylan Inc. (Nasdaq: MYL) today confirmed that the United States District Court for the Eastern District of Virginia has ruled invalid a patent, United States Patent No. RE44,048, related to Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Mylan opens Critical Care Segment in India
M2 - Wed Mar 12, 8:19AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the launch of a Critical Care segment in India, by its subsidiary Mylan Pharmaceuticals Private Limited.
Mylan proposes JoEllen Lyons Dillon for election to board of directors
M2 - Wed Mar 12, 8:04AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the nomination of JoEllen Lyons Dillon as a candidate for election to Mylan's Board.
Mylan introduces Naloxone Hydrochloride Injection
M2 - Wed Mar 12, 7:59AM CDT
Pharmaceutical company Mylan Inc ((NASDAQ GS:MYL) announced on Tuesday the launch of Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
Mylan Launches Naloxone Hydrochloride Injection
PR Newswire - Tue Mar 11, 2:03PM CDT
Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Mylan's Naloxone Hydrochloride Injection is preservative free and not made with natural rubber latex.
Mylan Introduces Critical Care Segment in India
PR Newswire - Tue Mar 11, 2:00PM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome®, a leading anti-fungal, is one of the first critical care products Mylan is offering. Critical care is a leading therapeutic category in India, with $2.6 billion* in annual sales.1
Mylan Nominates JoEllen Lyons Dillon for Election to Board of Directors
PR Newswire - Tue Mar 11, 11:06AM CDT
Mylan Inc. (Nasdaq: MYL) today announced that its Board of Directors has nominated JoEllen Lyons Dillon as a candidate for election to Mylan's Board at the 2014 Annual Meeting of Shareholders to be held on April 11, 2014. If elected, Dillon will replace C.B. (Sonny) Todd, who will become Director Emeritus effective April 12, 2014 and was not nominated for reelection at the 2014 Annual Meeting. If Mylan's shareholders elect all candidates nominated by the Board at the 2014 Annual Meeting, including Dillon, Mylan's Board will consist of 13 directors, 10 of whom will be independent and 4 of whom will be women.
SmarTrend Watching for Potential Rebound in Shares of Mylan After 2.64% Loss
Comtex SmarTrend(R) - Mon Mar 10, 3:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.31 to a high of $54.84. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $53.65 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Mylan to Potentially Rebound After Falling 2.64% Yesterday
Comtex SmarTrend(R) - Mon Mar 10, 3:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.31 to a high of $54.84. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $53.65 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Mylan Up 17.7% Since SmarTrend Uptrend Call (MYL)
Comtex SmarTrend(R) - Mon Mar 10, 10:00AM CDT
SmarTrend identified an Uptrend for Mylan (NASDAQ:MYL) on February 14th, 2014 at $46.13. In approximately 3 weeks, Mylan has returned 17.73% as of today's recent price of $54.31.
Earnings Look Back: Mylan Is Down 2.5% Since Reporting Quarterly Results 1 Week Ago (MYL)
Comtex SmarTrend(R) - Mon Mar 10, 7:30AM CDT
When Mylan (NASDAQ:MYL) reported earnings a week ago on February 27th, 2014, analysts, on average, expected the company to report earnings of $0.75 on sales of $1.8 billion. The company actually reported EPS of $0.78 on sales of $1.8 billion, beating EPS estimates by $0.03 and beating revenue estimates by $3.1 million. Shares of Mylan have slipped from $56.27 to $54.86, representing a loss of 2.5%, since the company reported earnings 11 days ago.
Is Mylan a Good Buy?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
As branded drugs have become more complicated and global growth has become more important to generic franchises, scale matters more than ever. That's a definite check mark in the plus column for Mylan , as it is among the largest generic drug...
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
Today's 3 Worst Stocks in the S&P 500
John Divine, The Motley Fool - Motley Fool - Wed Mar 05, 6:26PM CST
The S&P 500 Index pulled back ever-so-gently from its record close yesterday, as a gauge of U.S. private sector employment came in below expectations. The ADP employment report, often considered an indicator for the Labor Deartment's monthly...
Mylan Rises 3.03% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Mar 04, 5:41PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.11 to a high of $57.52. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $57.07 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 3.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 04, 5:40PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.11 to a high of $57.52. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $57.07 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch For Today's Momo Momentum Stock: Mylan (MYL)
at The Street - Tue Mar 04, 8:48AM CST
Trade-Ideas LLC identified Mylan (MYL) as a momo momentum candidate
Mylan Comments on Favorable Ruling in Generic Celebrex® Patent Suit
PR Newswire - Thu Mar 13, 5:30AM CDT
Mylan Inc. (Nasdaq: MYL) today confirmed that the United States District Court for the Eastern District of Virginia has ruled invalid a patent, United States Patent No. RE44,048, related to Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Mylan opens Critical Care Segment in India
M2 - Wed Mar 12, 8:19AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the launch of a Critical Care segment in India, by its subsidiary Mylan Pharmaceuticals Private Limited.
Mylan proposes JoEllen Lyons Dillon for election to board of directors
M2 - Wed Mar 12, 8:04AM CDT
Pharmaceutical company Mylan Inc (NASDAQ GS:MYL) announced on Tuesday the nomination of JoEllen Lyons Dillon as a candidate for election to Mylan's Board.
Mylan introduces Naloxone Hydrochloride Injection
M2 - Wed Mar 12, 7:59AM CDT
Pharmaceutical company Mylan Inc ((NASDAQ GS:MYL) announced on Tuesday the launch of Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
Mylan Launches Naloxone Hydrochloride Injection
PR Newswire - Tue Mar 11, 2:03PM CDT
Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Mylan's Naloxone Hydrochloride Injection is preservative free and not made with natural rubber latex.
Mylan Introduces Critical Care Segment in India
PR Newswire - Tue Mar 11, 2:00PM CDT
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome®, a leading anti-fungal, is one of the first critical care products Mylan is offering. Critical care is a leading therapeutic category in India, with $2.6 billion* in annual sales.1
Mylan Nominates JoEllen Lyons Dillon for Election to Board of Directors
PR Newswire - Tue Mar 11, 11:06AM CDT
Mylan Inc. (Nasdaq: MYL) today announced that its Board of Directors has nominated JoEllen Lyons Dillon as a candidate for election to Mylan's Board at the 2014 Annual Meeting of Shareholders to be held on April 11, 2014. If elected, Dillon will replace C.B. (Sonny) Todd, who will become Director Emeritus effective April 12, 2014 and was not nominated for reelection at the 2014 Annual Meeting. If Mylan's shareholders elect all candidates nominated by the Board at the 2014 Annual Meeting, including Dillon, Mylan's Board will consist of 13 directors, 10 of whom will be independent and 4 of whom will be women.
SmarTrend Watching for Potential Rebound in Shares of Mylan After 2.64% Loss
Comtex SmarTrend(R) - Mon Mar 10, 3:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.31 to a high of $54.84. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $53.65 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Mylan to Potentially Rebound After Falling 2.64% Yesterday
Comtex SmarTrend(R) - Mon Mar 10, 3:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.31 to a high of $54.84. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $53.65 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Mylan Up 17.7% Since SmarTrend Uptrend Call (MYL)
Comtex SmarTrend(R) - Mon Mar 10, 10:00AM CDT
SmarTrend identified an Uptrend for Mylan (NASDAQ:MYL) on February 14th, 2014 at $46.13. In approximately 3 weeks, Mylan has returned 17.73% as of today's recent price of $54.31.
Earnings Look Back: Mylan Is Down 2.5% Since Reporting Quarterly Results 1 Week Ago (MYL)
Comtex SmarTrend(R) - Mon Mar 10, 7:30AM CDT
When Mylan (NASDAQ:MYL) reported earnings a week ago on February 27th, 2014, analysts, on average, expected the company to report earnings of $0.75 on sales of $1.8 billion. The company actually reported EPS of $0.78 on sales of $1.8 billion, beating EPS estimates by $0.03 and beating revenue estimates by $3.1 million. Shares of Mylan have slipped from $56.27 to $54.86, representing a loss of 2.5%, since the company reported earnings 11 days ago.
Is Mylan a Good Buy?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
As branded drugs have become more complicated and global growth has become more important to generic franchises, scale matters more than ever. That's a definite check mark in the plus column for Mylan , as it is among the largest generic drug...
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
Today's 3 Worst Stocks in the S&P 500
John Divine, The Motley Fool - Motley Fool - Wed Mar 05, 6:26PM CST
The S&P 500 Index pulled back ever-so-gently from its record close yesterday, as a gauge of U.S. private sector employment came in below expectations. The ADP employment report, often considered an indicator for the Labor Deartment's monthly...
Mylan Rises 3.03% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Mar 04, 5:41PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.11 to a high of $57.52. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $57.07 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 3.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 04, 5:40PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.11 to a high of $57.52. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $57.07 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch For Today's Momo Momentum Stock: Mylan (MYL)
at The Street - Tue Mar 04, 8:48AM CST
Trade-Ideas LLC identified Mylan (MYL) as a momo momentum candidate
(0)
(0)Mylan Inc. (MYL) Stock Research Links
Scroll down for more posts ▼